Christian Chavy has been appointed CEO of French biopharmaceutical company Stallergenes and will take over from Roberto Gradnik at the end of this month.
Chavy has worked for the ARES Life Science healthcare investment fund since 2010 and prior to that he served as president of global operations for Actelion Pharmaceuticals.
Before joining Actelion he was vice president of Serono’s reproductive medicine strategic unit and chairman of the company’s French subsidiary.
Stallergenes said Chavy’s appointment would enable it to “pursue its strategy” and to its work in promising immunotherapy markets – the US in particular.
Meanwhile Gradnick, who joined Stallergenes in October 2011 as deputy CEO before taking up the post of CEO three months later, will provide consultancy services to the board of directors during a four-month transitional period.